Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

962 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A. Musto P, et al. Among authors: cavallo f. Leuk Res. 2006 Mar;30(3):283-5. doi: 10.1016/j.leukres.2005.06.027. Epub 2005 Aug 18. Leuk Res. 2006. PMID: 16111749 Free article. Clinical Trial.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: cavallo f. Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20. Blood. 2004. PMID: 15265788 Free article. Clinical Trial.
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M. Palumbo A, et al. Among authors: cavallo f. Clin Lymphoma Myeloma. 2006 May;6(6):475-7. doi: 10.3816/CLM.2006.n.028. Clin Lymphoma Myeloma. 2006. PMID: 16796778 Clinical Trial.
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Palumbo A, et al. Among authors: cavallo f. Blood. 2007 Apr 1;109(7):2767-72. doi: 10.1182/blood-2006-08-042275. Blood. 2007. PMID: 17148584 Free article. Clinical Trial.
The treatment of the elderly multiple myeloma patients.
Cavallo F, Ambrosini MT, Rus C, Boccadoro M, Palumbo A. Cavallo F, et al. Leuk Lymphoma. 2007 Mar;48(3):469-80. doi: 10.1080/10428190601059852. Leuk Lymphoma. 2007. PMID: 17454586 Review.
962 results